Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 5/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20075362 | 0.89 | WNT1 (0.39) | P2RY14ALOX5APFEN1JAK2MAPT | |
| SCHEMBL20075350 | 0.88 | P2RY14 (0.47) | P2RY14MCHR1KDM1AHDAC1ALOX5AP | |
| SCHEMBL20074608 | 0.87 | CNR1 (0.43) | JAK2 | |
| SCHEMBL20074601 | 0.86 | P2RY14 (0.48) | P2RY14MCHR1KDM1AHDAC1ALOX5AP | |
| SCHEMBL20074802 | 0.85 | P2RY14 (0.45) | P2RY14MCHR1KDM1AHDAC1ALOX5AP | |
| SCHEMBL19641943 | 0.80 | P2RY14 (0.47) | P2RY14MCHR1ALOX5APFEN1JAK2 | |
| SCHEMBL20074610 | 0.77 | HTR6 (0.42) | P2RY14MAPT | |
| SCHEMBL20075391 | 0.77 | GSK3B (0.51) | MAPT | |
| SCHEMBL19641967 | 0.76 | P2RY14 (0.44) | P2RY14MCHR1 | |
| SCHEMBL19642037 | 0.76 | P2RY14 (0.48) | P2RY14MCHR1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | claimed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | claimed |
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-08-01 | — | — | US | disclosed |
| CN-109563049-A | imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | P2RY14 2903/4885MCHR1 906/4885KDM1A 466/4885 |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | SLC1A1, SLC1A3, SLC1A2 | P2RY14 2903/4885MCHR1 906/4885KDM1A 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.